ImmuCell Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum and approved all proposals, including director elections, executive compensation, a new stock plan, a charter amendment, and auditor ratification. A major two-phase manufacturing expansion was announced to support sustained product demand and growth.
-
Record Q1 2026 revenue and net income growth driven by strong Tri-Shield sales, margin expansion, and increased U.S. market share. Capacity and sales force investments support continued growth, with international expansion and plant upgrades underway.
Fiscal Year 2025
-
2025 saw 4.3% sales growth to $27.6M, gross margin rise to 41%, and a $3.3M operating income swing, driven by expanded capacity and a strategic focus on First Defense. Net loss narrowed to $1M despite significant non-cash write-downs.
-
Strategic focus shifted to First Defense after FDA setbacks for Re-Tain, driving strong domestic sales and operational improvements. Q4 2025 sales reached $7.6M, with Tri-Shield up 41.3% year-over-year, while international sales declined. Asset repurposing and team expansion support future growth.
-
Reported a strong financial turnaround with net income of $1.8 million and gross margin rising to 43% for the nine months ended September 30, 2025. Domestic sales showed positive momentum, and new leadership is focused on operational excellence and growth initiatives.
-
Focused on antibody-based products for calf health, the company has doubled manufacturing capacity and achieved strong financial growth in early 2025. Re-Tain, a new non-antibiotic mastitis treatment, is in late-stage FDA review, and leadership transition is planned for year-end.
-
Q2 2025 saw strong sales and margin growth, driven by restored First Defense supply and inventory rebuild, though a temporary sales boost is expected to normalize in H2. Re-Tain's commercial launch remains delayed pending FDA approval, with all expiring inventory used for investigational studies.
-
Production capacity has doubled, driving strong sales and margin recovery after past disruptions. First Defense now offers broader pathogen coverage and immediate immunity, while Re-Tain is set for investigational use in 2025 as FDA approval is pending.
-
Record Q1 2025 sales and gross margin expansion were driven by strong First Defense demand and operational improvements. Backlog reduction and new product launches position the company for continued growth, while Re-Tain advances via investigational use pending FDA approval.
-
Key milestones are expected in 2025, with First Defense expanding its market presence and Re-Tain nearing FDA approval. Manufacturing challenges have been overcome, and new product formats aim to capture more market share while reducing antibiotic use.
Fiscal Year 2024
-
Sales grew 52% year-over-year in Q4 and 2024, with gross margin and EBITDA rebounding sharply after resolving production issues. Awaiting FDA approval for Re-Tain, while new product formats and increased capacity position the company for further growth.
-
Sales rose sharply year-over-year, driven by strong demand for First Defense, while gross margin improved but remains below target due to higher costs and product mix. Remediation of production issues and an ATM offering strengthened operations and cash position.
-
Strong sales growth and improved production capacity drove higher output, but gross margin remains below target due to past contamination and yield issues. Operational improvements and yield initiatives are underway, with regulatory progress for Re-Tain ongoing.